JP2021534740A5 - - Google Patents
Info
- Publication number
- JP2021534740A5 JP2021534740A5 JP2021507503A JP2021507503A JP2021534740A5 JP 2021534740 A5 JP2021534740 A5 JP 2021534740A5 JP 2021507503 A JP2021507503 A JP 2021507503A JP 2021507503 A JP2021507503 A JP 2021507503A JP 2021534740 A5 JP2021534740 A5 JP 2021534740A5
- Authority
- JP
- Japan
- Prior art keywords
- genetically modified
- modified hematopoietic
- nucleic acid
- nucleotide sequence
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862718579P | 2018-08-14 | 2018-08-14 | |
| US201862718491P | 2018-08-14 | 2018-08-14 | |
| US62/718,579 | 2018-08-14 | ||
| US62/718,491 | 2018-08-14 | ||
| PCT/US2019/046550 WO2020037066A1 (en) | 2018-08-14 | 2019-08-14 | Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021534740A JP2021534740A (ja) | 2021-12-16 |
| JP2021534740A5 true JP2021534740A5 (enExample) | 2022-08-22 |
| JP7456638B2 JP7456638B2 (ja) | 2024-03-27 |
Family
ID=69524868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021507503A Active JP7456638B2 (ja) | 2018-08-14 | 2019-08-14 | クレブス回路を調節するトランス代謝分子と組み合わせたキメラ抗原受容体ポリペプチド、及び、それらの治療的使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12077785B2 (enExample) |
| EP (1) | EP3837353A4 (enExample) |
| JP (1) | JP7456638B2 (enExample) |
| KR (1) | KR20210045418A (enExample) |
| CN (1) | CN112840019B (enExample) |
| AU (1) | AU2019321540B2 (enExample) |
| BR (1) | BR112021001694A2 (enExample) |
| CA (1) | CA3108126A1 (enExample) |
| IL (1) | IL280322B2 (enExample) |
| MX (1) | MX2021001771A (enExample) |
| SG (1) | SG11202101284UA (enExample) |
| WO (1) | WO2020037066A1 (enExample) |
| ZA (1) | ZA202100993B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020037066A1 (en) * | 2018-08-14 | 2020-02-20 | Unum Therapeutics Inc. | Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| CA3182769A1 (en) * | 2020-06-15 | 2021-12-23 | Andrew P. Mazar | Precision radioimmunotherapeutic targeting of the urokinase plasminogen activator receptor (upar) for treatment of severe covid-19 disease |
| EP4192586A4 (en) * | 2020-08-10 | 2024-10-16 | Arizona Board of Regents on behalf of Arizona State University | Metabolism-based chimeric antigen receptors and methods of treatment |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| MX2024004009A (es) * | 2021-09-27 | 2024-06-19 | Sotio Biotech Inc | Polipéptidos receptores quiméricos en combinación con moléculas transmetabólicas que redirigen metabolitos de glucosa fuera de la vía de la glucólisis y usos terapéuticos de estos. |
| CA3237201A1 (en) | 2021-11-16 | 2023-05-25 | Sotio Biotech Inc. | Treatment of myxoid/round cell liposarcoma patients |
| EP4249588A1 (en) * | 2022-03-22 | 2023-09-27 | Universität Basel Vizerektorat Forschung | Cellular therapy |
| WO2024015995A2 (en) * | 2022-07-15 | 2024-01-18 | Albert Einstein College Of Medicine | Chimeric antigen receptors comprising a tmigd2 costimulatory domain and associated methods of using the same |
| WO2024040207A1 (en) | 2022-08-19 | 2024-02-22 | Sotio Biotech Inc. | Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof |
| US20260053924A1 (en) | 2022-08-19 | 2026-02-26 | Sotio Biotech Inc. | Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof |
| WO2024215987A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES |
| EP4694916A1 (en) | 2023-04-14 | 2026-02-18 | SOTIO Biotech Inc. | Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists |
| WO2026052052A1 (en) * | 2024-09-06 | 2026-03-12 | Jw Therapeutics R & D (Shanghai) Co., Ltd. | Polypeptide for the treatment of diseases associated with gpc3 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4650764A (en) | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US4980289A (en) | 1987-04-27 | 1990-12-25 | Wisconsin Alumni Research Foundation | Promoter deficient retroviral vector |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| US5124263A (en) | 1989-01-12 | 1992-06-23 | Wisconsin Alumni Research Foundation | Recombination resistant retroviral helper cell and products produced thereby |
| EP0832980B1 (en) | 1989-01-23 | 2002-06-19 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| EP1001032A3 (en) | 1989-08-18 | 2005-02-23 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| ATE237694T1 (de) | 1991-08-20 | 2003-05-15 | Us Gov Health & Human Serv | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| EP0650370A4 (en) | 1992-06-08 | 1995-11-22 | Univ California | METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES. |
| EP0644946A4 (en) | 1992-06-10 | 1997-03-12 | Us Health | VECTOR PARTICLES RESISTANT TO INACTIVATION BY HUMAN SERUM. |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| EP0673431A1 (en) | 1992-12-03 | 1995-09-27 | Genzyme Corporation | Gene therapy for cystic fibrosis |
| EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
| AU7477394A (en) | 1993-07-30 | 1995-03-27 | University Of Medicine And Dentistry Of New Jersey | Efficient gene transfer into primary lymphocytes |
| DE69435223D1 (de) | 1993-10-25 | 2009-09-03 | Canji Inc | Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung |
| US5756910A (en) | 1996-08-28 | 1998-05-26 | Burgett, Inc. | Method and apparatus for actuating solenoids in a player piano |
| EP0968284B1 (en) | 1996-11-20 | 2006-12-13 | Introgen Therapeutics, Inc. | An improved method for the production and purification of adenoviral vectors |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| AU2474700A (en) | 1998-12-01 | 2000-06-19 | Genentech Inc. | Secreted amd transmembrane polypeptides and nucleic acids encoding the same |
| JP2002541845A (ja) | 1999-04-16 | 2002-12-10 | セルテック セラピューティックス リミテッド | 合成膜貫通成分 |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| AU2005256113B2 (en) | 2004-07-09 | 2011-02-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody |
| JP5779090B2 (ja) | 2008-04-09 | 2015-09-16 | マックスサイト インコーポレーティッド | 新規に単離された細胞の治療組成物の操作および送達 |
| DK3178835T3 (da) | 2009-02-03 | 2019-06-24 | Amunix Pharmaceuticals Inc | Forlængede rekombinante polypeptider og sammensætninger omfattende samme |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| KR20140060541A (ko) | 2011-09-16 | 2014-05-20 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 rna 조작된 t 세포 |
| AU2013266243A1 (en) | 2012-05-24 | 2014-12-18 | Beth Israel Deaconess Medical Center, Inc. | Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer |
| US10144770B2 (en) | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
| KR102308597B1 (ko) | 2013-10-17 | 2021-10-01 | 내셔널 유니버시티 오브 싱가포르 | 다중 종양에 대항하여 항체-의존성 세포 세포독성을 촉발시키는 키메라 수용체 |
| WO2016040441A1 (en) | 2014-09-09 | 2016-03-17 | Unum Therapeutics | Chimeric receptors and uses thereof in immune therapy |
| ES2851123T1 (es) | 2014-09-26 | 2021-09-03 | Baylor College Medicine | Receptores quiméricos de antígeno específicos de glipicano-3 para inmunoterapia adoptiva |
| US10829735B2 (en) | 2015-07-21 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Methods for improving the efficacy and expansion of immune cells |
| WO2017075537A1 (en) | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
| US11020429B2 (en) * | 2015-11-05 | 2021-06-01 | Juno Therapeutics, Inc. | Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy |
| EP3402571A4 (en) * | 2016-01-15 | 2019-08-28 | The J. David Gladstone Institutes | METHOD FOR THE TREATMENT OF DISORDERS BY METABOLIC CONTROL OF T-CELL DIFFERENTIATION |
| EP3430036A4 (en) | 2016-03-18 | 2019-08-14 | Unum Therapeutics | MODIFIED CHIMERIC RECEPTORS AND USES IN IMMUNOTHERAPY |
| KR102614675B1 (ko) | 2016-04-15 | 2023-12-19 | 메모리얼 슬로안 케터링 캔서 센터 | 유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법 |
| CN110494162A (zh) | 2017-01-30 | 2019-11-22 | 优努姆治疗公司 | 改良的抗体-偶联t细胞受体构建体及其治疗用途 |
| WO2020010110A1 (en) | 2018-07-03 | 2020-01-09 | Unum Therapeutics Inc. | Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof |
| WO2020028572A2 (en) * | 2018-08-01 | 2020-02-06 | Unum Therapeutics Inc. | ANTIBODY-COUPLED T CELL RECEPTORS (ACTRs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF |
| WO2020037066A1 (en) * | 2018-08-14 | 2020-02-20 | Unum Therapeutics Inc. | Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof |
| WO2020037142A1 (en) * | 2018-08-17 | 2020-02-20 | Yale University | Compositions and methods for high-throughput activation screening to boost t cell effector function |
| CA3118889A1 (en) * | 2018-11-07 | 2020-05-14 | Sotio, LLC | Anti-gpc3 chimeric antigen receptors (cars) in combination with trans co-stimulatory molecules and therapeutic uses thereof |
| EP3942023A1 (en) * | 2019-03-18 | 2022-01-26 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
| JP2023531378A (ja) * | 2020-05-28 | 2023-07-24 | エーゼットセラピーズ， インコーポレイテッド | 神経変性疾患を治療するためのＣＡＲ－Ｔｒｅｇ系療法 |
| MX2024004009A (es) * | 2021-09-27 | 2024-06-19 | Sotio Biotech Inc | Polipéptidos receptores quiméricos en combinación con moléculas transmetabólicas que redirigen metabolitos de glucosa fuera de la vía de la glucólisis y usos terapéuticos de estos. |
| CA3237201A1 (en) * | 2021-11-16 | 2023-05-25 | Sotio Biotech Inc. | Treatment of myxoid/round cell liposarcoma patients |
-
2019
- 2019-08-14 WO PCT/US2019/046550 patent/WO2020037066A1/en not_active Ceased
- 2019-08-14 IL IL280322A patent/IL280322B2/en unknown
- 2019-08-14 US US17/268,345 patent/US12077785B2/en active Active
- 2019-08-14 CN CN201980056166.6A patent/CN112840019B/zh active Active
- 2019-08-14 SG SG11202101284UA patent/SG11202101284UA/en unknown
- 2019-08-14 BR BR112021001694-5A patent/BR112021001694A2/pt unknown
- 2019-08-14 CA CA3108126A patent/CA3108126A1/en active Pending
- 2019-08-14 JP JP2021507503A patent/JP7456638B2/ja active Active
- 2019-08-14 KR KR1020217006593A patent/KR20210045418A/ko not_active Ceased
- 2019-08-14 EP EP19849543.4A patent/EP3837353A4/en active Pending
- 2019-08-14 MX MX2021001771A patent/MX2021001771A/es unknown
- 2019-08-14 AU AU2019321540A patent/AU2019321540B2/en active Active
-
2021
- 2021-02-12 ZA ZA2021/00993A patent/ZA202100993B/en unknown
-
2024
- 2024-07-25 US US18/784,028 patent/US20240376442A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021536265A5 (enExample) | ||
| JP2021529559A5 (enExample) | ||
| Blanco et al. | Bispecific immunomodulatory antibodies for cancer immunotherapy | |
| US20240059754A1 (en) | Chimeric antigen receptors and enhancement of anti-tumor activity | |
| KR102879284B1 (ko) | 항-메소텔린 키메라 항원 수용체(car) 작제물 및 이의 용도 | |
| Nolan et al. | Bypassing immunization: optimized design of “designer T cells” against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA | |
| CN105384825B (zh) | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 | |
| US20190023764A1 (en) | Car having replicated binding motifs in a co-stimulatory domain | |
| Karches et al. | Bispecific antibodies enable synthetic agonistic receptor-transduced T cells for tumor immunotherapy | |
| EP3169703B1 (en) | Chimeric antigen receptor and its use | |
| US20240342283A1 (en) | ROR1 CAR or ROR1 / CD19 Dual CAR T Cells for the Treatment of Tumors | |
| JP2024536859A5 (enExample) | ||
| CN109280086B (zh) | 一种肿瘤微环境特异性活化的缺氧诱导型嵌合抗原受体 | |
| JP2024023228A5 (enExample) | ||
| BR112019017629A2 (pt) | receptor de união ao antígeno, polinucleotídeo isolado, vetor, célula t transduzida, métodos para o tratamento de uma doença e para induzir a lise, utilização do receptor e receptor | |
| US20180105595A1 (en) | Time and space adjustable system for inhibiting pathological target cells | |
| Pameijer et al. | Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor | |
| EP3055330A1 (en) | Molecule | |
| IL280322B2 (en) | Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof | |
| US20220306719A1 (en) | Ultramodular igg3-based spacer domain and multi-function site for implementation in chimeric antigen receptor design | |
| US20220298223A1 (en) | B CELL TARGETED PARALLEL CAR (pCAR) THERAPEUTIC AGENTS | |
| WO2019115818A2 (en) | Pooling signaling and costimulatory domains in flexible car design | |
| CN116033919A (zh) | 用于免疫细胞中衔接子的诱导型表达的系统 | |
| WO2021027785A1 (zh) | 共表达趋化因子受体的免疫效应细胞 | |
| EP4351635A1 (en) | Antibody-nkg2d ligand domain fusion protein |